Novel agents that target different cellular pathways have been related to a wide spectrum of ophthalmologic adverse events. We discuss ophthalmologic toxicities associated with molecular targeted therapies, with particular focus on MEK retinopathy, including its nomenclature, incidence, symptoms and management.
from Cancer via ola Kala on Inoreader http://ift.tt/21UuaHt
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου